Motus GI to Release Fourth Quarter 2019 Results and Provide a Business Update on March 30th

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and year ended December 31, 2019 financial results on Monday, March 30, 2020, after the market close. Management will also host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

 

Conference Call and Webcast

Date and Time:

 

Monday, March 30th @ 4:30 p.m. ET

Domestic:

 

877-407-0792

International:

 

201-689-8263

Passcode:

 

13699879

Webcast:

 

http://www.motusgi.com/ or http://public.viavid.com/index.php?id=138357

A replay of the webcast will be archived on the Motus GI website, www.motusgi.com, for 90 days following the event.

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better quality exam. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and enhancing the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Contacts

Investor Contact:
Bob Yedid

LifeSci Advisors

(646) 597-6989

bob@lifesciadvisors.com

Media Contact:
Gloria Gasaatura

LifeSci Public Relations

(646) 627-8387

ggasaatura@lifescipublicrelations.com

Staff

Recent Posts

Avio Health Launches World’s First Functional Medicine LLM for Emagene Life, Transforming Personalized Healthcare

KUALA LUMPUR, Malaysia, June 27, 2025 /PRNewswire/ -- Avio Health, a deep-tech company dedicated to advancing healthcare through data analytics and machine learning, today announced…

1 hour ago

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that…

1 hour ago

Vinamilk Showcases Science-Driven Innovation and Wins Prestigious Awards at Global Dairy Congress 2025

AMSTERDAM, June 26, 2025 /PRNewswire/ -- Vinamilk, Vietnam's leading dairy company, presented its science-driven innovation…

7 hours ago

Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and…

13 hours ago

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new…

13 hours ago